



## Evekeo<sup>®</sup> (amphetamine) – First-time generic

- On September 30, 2018, Amneal Pharmaceuticals launched an [AB-rated](#) generic version of Arbor Pharmaceuticals' [Evekeo \(amphetamine\)](#) tablets.
  - Amphetamine is a Schedule II controlled substance.
- Evekeo is indicated for the treatment of narcolepsy; attention deficit disorder with hyperactivity (ADHD); and exogenous obesity.
- Amphetamine is also available as the branded products: [Adzenys ER<sup>™</sup>](#) extended-release oral suspension, [Adzenys XR-ODT<sup>™</sup>](#) extended-release orally disintegrating tablets, and [Dyanavel<sup>®</sup> XR](#) extended-release oral suspension.
  - Extended-release amphetamine is only indicated for the treatment of ADHD.
- Evekeo carries a boxed warning for abuse and dependence potential and cardiovascular adverse events.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.